Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2013

View Archived Issues

Nintedanib shows no activity against recurrent high-grade gliomas

Phase II trial planned after phase I study completed with selumetinib in children with gliomas

Bispecific hexavalent antibody shows promise for treating lupus

ImmunoCellular Therapeutics reports phase II data for ICT-107

Integral Molecular generates MAbs against the P2X3 ion channel

KaloBios Pharmaceuticals presents phase I results for KB-004

AGI-14100 significantly reduces tumor burden in IDH1-mutant mouse model

Swiss group discloses new MPC modulators

Convergence Pharmaceuticals prepares novel sodium channel blockers for pain

New potassium channel modulators patented by Autifony Therapeutics

Piramal Enterprises synthesizes new pyrimidine compounds

Korean researchers present new antibodies that bind to RANKL for bone disorders

Mallinckrodt completes clinical trials of MNK-155

Novel Trk-A inhibitors designed by Merck & Co.

SPX-106T lowers cholesterol and triglyceride levels and prevents weight gain in vivo

Canadian approval for Lemtrada

FDA advisory committee votes in favor of Oralair for grass pollen allergy

Stem cell candidate receives orphan drug designation in Japan

FDA advisory committee recommends approval of dapagliflozin

Celator's phase III study of CPX-351 for AML cleared to continue by DSMB

CDRD Ventures launches spin-off company Kairos Therapeutics

Dementia Consortium launched in the UK to advance drug development

FDA approves Complera for patients with HIV switching from a stable regimen

Endocyte begins phase I study of EC-1456 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...